Perspective
The inter-ministerial conference on immunization held at African Union headquarters in February 2016 came, by coincidence, almost exactly 30 years after the first international immunization conference I attended, convened by World Health Organization (WHO) and UNICEF in Mbabane in December 1985. Times have changed. In 1985, there was no Gates Foundation, there was no Global Vaccine Alliance (GAVI Alliance), and there was no global commitment to polio eradication. Three items which figured prominently on the Addis Ababa program were quite absent from many earlier meetings: 1) the economic justification for vaccination and eradication; 2) the role of parliamentarians, religious leaders and civil society organizations (CSOs) in advocacy and accountability for vaccination programs, 3) vaccine financing.
The economic justification for vaccination and eradication
Economists were not much to be seen in the vaccination programs of 30 years ago. Vaccination, like virtue, was thought to be its own reward. This assumption was based on the erroneous premise that finance ministers would support vaccination programs because they were a global public good, like clean air. The multiple calls on scarce public resources have generated much academic work to build the case for vaccination. The most quoted figure from the Addis Ababa conference was based on the published work of Ozawa and colleagues, from Johns Hopkins, showing a benefit: cost ratio of 16:1 for childhood vaccinations in low-and middle-income countries. Their work [1] is a powerful advocacy tool for use with hard-nosed finance ministers, who must say no to health ministries as often as they say yes. This need is all the more pressing as vaccines used and vaccine procurement bills have seen an astronomical rise. Under these conditions, it is not surprising that 9 African countries are in default on their co-payments for internationally procured vaccines. When this information becomes widely known, pressure builds on governments to take corrective measures.
One parliamentarian from Kinshasa illustrated the point during the Addis Ababa conference. Taken as a whole, the religious participation in vaccination is a decided plus.
Vaccine Financing
The world"s vaccine bill is on the rise, as countries which used to vaccinate against six diseases now vaccinate against 10 to 12 diseases with vaccines which, at as much $5 a dose, are far less affordable than in the past. Thirty years ago, the Republic of Kenya The international community has increased its spending on vaccines, as have developing countries. But gaps remain. Donal
Brown, speaking for one major donor (DFID), made the following comments from a partner perspective.
"There is enormous competition for donor resources. Everything is a priority, but you can"t fund anything. Spending on humanitarian relief last year was the highest in history. EPI competes with other priorities.
The Johns Hopkins benefit: cost figure of 16:1 comes to 44:1 when you incorporate all benefits. Immunization is the best buy. It is, therefore, something that developing countries should be willing to finance. We"ve looked at costs of immunization as a part of government expenditure. Most countries can pay for vaccination. It is a question of choice. There is a role here for community service organizations (CSOs). Revenues of African governments have almost tripled in the last decade. Donors cannot fill that gap. GAVI graduation policy (for countries with per capita GNI greater than USD 1500) is well considered.
It"s a question of willingness to pay, not ability to pay. We need better engagement between finance ministries and health ministries.
It"s not a donor issue."
Pooled procurement of vaccines, as in the Region of the Americas, was discussed by some participants in Addis Ababa. Another possible solution raised was the production of WHO prequalified vaccines in Africa. This is already done, by the Pasteur Institute of Dakar, for yellow fever vaccine. Chris Elias, of the Gates Foundation, Foundation (BMGF) has been working on production of veterinary vaccines, costing $50 million. The regulatory challenge is lower for veterinary than for human vaccines.
Future Perspectives
With polio eradication in perspective, African countries are beginning to look for new targets for elimination, including measles and, perhaps, rubella. What are the preconditions to be met? The ideas emerging from the Addis Ababa conference pointed to the following imperatives: 
